Telatinib (BioDeep_00000771853)
代谢物信息卡片
化学式: C20H16ClN5O3 (409.0942)
中文名称: 替拉替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl
InChI: InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- B Benjamin, M Sahu, U Bhatnagar, D Abhyankar, N R Srinivas. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?.
Arzneimittel-Forschung.
2012 Apr; 62(4):194-201. doi:
10.1055/s-0031-1299772. [PMID: 22290114] - M H G Langenberg, P O Witteveen, J Roodhart, M P Lolkema, H M W Verheul, M Mergui-Roelvink, E Brendel, J Krätzschmar, B Loembé, A Nol-Boekel, O Christensen, J H M Schellens, E E Voest. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
2011 Nov; 22(11):2508-2515. doi:
10.1093/annonc/mdq767. [PMID: 21378200] - Klaus Mross, Annette Frost, Max E Scheulen, Jürgen Krauss, Dirk Strumberg, Beate Schultheiss, Ulrike Fasol, Martin Büchert, Jörn Krätzschmer, Heinz Delesen, Prabhu Rajagopalan, Olaf Christensen. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.
Vascular cell.
2011 Jul; 3(?):16. doi:
10.1186/2045-824x-3-16. [PMID: 21801343] - Brian I Rini, Darrel P Cohen, Dongrui R Lu, Isan Chen, Subramanian Hariharan, Martin E Gore, Robert A Figlin, Michael S Baum, Robert J Motzer. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Journal of the National Cancer Institute.
2011 May; 103(9):763-73. doi:
10.1093/jnci/djr128. [PMID: 21527770] - Pankaj Bhargava, Murray O Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Current oncology reports.
2011 Apr; 13(2):103-11. doi:
10.1007/s11912-011-0154-3. [PMID: 21318618] - Charles Faselis, Michael Doumas, Vasilios Papademetriou. Common secondary causes of resistant hypertension and rational for treatment.
International journal of hypertension.
2011 Mar; 2011(?):236239. doi:
10.4061/2011/236239. [PMID: 21423678] - Ron J Keizer, Anubha Gupta, Melvin R Mac Gillavry, Mendel Jansen, Jantien Wanders, Jos H Beijnen, Jan H M Schellens, Mats O Karlsson, Alwin D R Huitema. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal of pharmacokinetics and pharmacodynamics.
2010 Aug; 37(4):347-63. doi:
10.1007/s10928-010-9164-2. [PMID: 20652729] - Ferry A L M Eskens, Neeltje Steeghs, Jaap Verweij, Johan L Bloem, Olaf Christensen, Leni van Doorn, Jan Ouwerkerk, Maja J A de Jonge, Johan W R Nortier, Joern Kraetzschmar, Prabhu Rajagopalan, Hans Gelderblom. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 Sep; 27(25):4169-76. doi:
10.1200/jco.2008.18.8193. [PMID: 19636022] - D Strumberg, B Schultheis, I A Adamietz, O Christensen, M Buechert, J Kraetzschmar, P Rajagopalan, M Ludwig, A Frost, S Steinbild, M E Scheulen, K Mross. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
British journal of cancer.
2008 Nov; 99(10):1579-85. doi:
10.1038/sj.bjc.6604724. [PMID: 19002179]
